19,723 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Bought by Wellington Management Group LLP

Wellington Management Group LLP acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 19,723 shares of the company's stock, valued at approximately $957,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in shares of Amphastar Pharmaceuticals by 10.9% during the third quarter. Victory Capital Management Inc. now owns 218,531 shares of the company's stock worth $10,605,000 after buying an additional 21,530 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth $11,070,000. Intech Investment Management LLC acquired a new stake in Amphastar Pharmaceuticals during the 2nd quarter worth $426,000. Los Angeles Capital Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at $785,000. Finally, Glenmede Trust Co. NA lifted its stake in shares of Amphastar Pharmaceuticals by 145.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 37,884 shares of the company's stock valued at $1,839,000 after purchasing an additional 22,439 shares during the period. 65.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the transaction, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This represents a 5.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William J. Peters sold 7,426 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,898,061.15. This represents a 7.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,533 shares of company stock valued at $1,987,482. Company insiders own 27.10% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AMPH. StockNews.com cut Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, November 1st. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $60.33.

Amphastar Pharmaceuticals Trading Down 0.6 %

Shares of AMPH traded down $0.25 during trading hours on Friday, reaching $39.14. The stock had a trading volume of 2,483,214 shares, compared to its average volume of 415,267. The company has a market cap of $1.88 billion, a P/E ratio of 13.05, a P/E/G ratio of 0.87 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a 50-day moving average of $46.63 and a 200 day moving average of $44.56.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.